Incyte (INCY) – Research Analysts’ Weekly Ratings Updates

A number of research firms have changed their ratings and price targets for Incyte (NASDAQ: INCY):

• 6/2/2026 – Incyte had its “market perform” rating reaffirmed by Citigroup Inc..
• 5/21/2026 – Incyte is now covered by Sanford C. Bernstein. They set a “market perform” rating and a $99.00 price target on the stock.
• 5/21/2026 – Incyte had its “buy” rating reaffirmed by HC Wainwright. They now have a $135.00 price target on the stock.
• 5/21/2026 – Incyte had its “buy” rating reaffirmed by Citigroup Inc..
• 5/21/2026 – Incyte was upgraded by Sanford C. Bernstein to “hold”.
• 5/4/2026 – Incyte had its “buy” rating reaffirmed by HC Wainwright. They now have a $135.00 price target on the stock.
• 4/29/2026 – Incyte had its price target raised by Oppenheimer Holdings, Inc. from $84.00 to $90.00. They now have a “market perform” rating on the stock.
• 4/29/2026 – Incyte had its price target raised by Stifel Nicolaus from $120.00 to $123.00. They now have a “buy” rating on the stock.
• 4/15/2026 – Incyte had its “buy” rating reaffirmed by HC Wainwright. They now have a $135.00 price target on the stock.

Insider Buying and Selling at Incyte

In other Incyte news, insider Pablo J. Cagnoni sold 18,667 shares of the firm’s stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $96.50, for a total transaction of $1,801,365.50. Following the completion of the sale, the insider directly owned 262,692 shares in the company, valued at $25,349,778. This trade represents a 6.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 16.20% of the company’s stock.

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.